Entities / Company
Boehringer Ingelheim.
German pharmaceutical company
- Reports this week
- 4
- Active events
- 5
- Connections
- 126
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Sheila Denton was appointed as General Counsel & Corporate Secretary at Boehringer Ingelheim.Some support1 report
-
Boehringer Ingelheim and Palatin Technologies reported $13.2 million in revenue from their Fiscal 2026 collaboration.Some support1 report
-
Boehringer Ingelheim reminds pet owners about preventive care in the Philippines.Some support1 report
-
Commission approved Boehringer storage structure plans and safety improvements for a railroad crossing.Some support1 report
-
AbbVie and Boehringer Ingelheim are engaging with financial advisory firms regarding potential deals and discussing M&A strategies in the competitive pharmaceutical market.Some support1 report
Earlier this month
One to three months ago
-
Boehringer supplies vaccines to England and collaborates with the VMD, leading to disease spread into Scotland.Some support2 reports
-
GSK and Boehringer Ingelheim are facing product liability claims regarding Zantac.Some support1 report
-
NHS partners with Boehringer Ingelheim to focus on a CKD early detection scheme.Some support1 report
-
American Lung Association received financial support from Boehringer Ingelheim and launched an awareness campaign.Some support1 report
Gone quiet
No new reports in 90+ days-
Major pharmaceutical companies, including Eli Lilly, AstraZeneca, and Boehringer Ingelheim, are adjusting investments and operations in Europe.Some support1 report1 development inside
-
Boehringer Ingelheim and Immunai announced a collaboration focused on T-cell targets for drug discovery.Some support1 report
-
Boehringer Ingelheim is seeking first-in-class assets in Korea.Some support1 report
-
Boehringer Ingelheim announced a partnership with Americares that aims to improve global access to medicine.Some support1 report
-
Proposed German drug pricing legislation is causing investment cuts and expansion cancellations for pharmaceutical companies.Some support1 report1 development inside
-
German drug pricing policy creates investment risk for pharmaceutical companies, including AstraZeneca and Boehringer Ingelheim.Some support1 report
-
German drug pricing reform is causing Eli Lilly and Boehringer Ingelheim to withdraw from European markets.Some support1 report
-
Dr. Kirk Shepard joined BP Logix's Life Sciences Strategic Advisory Board, leveraging his extensive background in the pharmaceutical industry.Some support1 report
-
Elanco, Zoetis, and Boehringer Ingelheim are noted for their leadership in the veterinary dermatology market.Some support1 report
-
Jyothis George held leadership roles at Amgen, Novo Nordisk, and Boehringer Ingelheim, driving strategic decisions on target indications and clinical trials.Some support1 report
-
Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement, receiving FDA feedback on a Pre-IND Briefing Document.Some support1 report
-
The FDA approved the Oncomine Dx Target Test, which identifies candidates for Boehringer Ingelheim's HERNEXEOS.Well supported4 reports
-
Elanco is joining the S&P MidCap 400 index, Boehringer Ingelheim launched a new swine vaccine, and Sarepta Therapeutics is being replaced in the index.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Boehringer Ingelheim this week
News at the entities that move Boehringer Ingelheim most-
Athens StructuralClarke County includes the city of Athens in Atlanta.Moves Boehringer Ingelheim
-
Pfizer OperationalDave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Moves Boehringer Ingelheim
-
England TransactionalAuthorities are investigating an incident at a base in Fairford, with possible links to Iran and Russia.Moves Boehringer Ingelheim
-
Johnson & Johnson OperationalP&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Moves Boehringer Ingelheim
-
Korea OperationalJamaica and Korea competed in the WorldSkills Competition.Moves Boehringer Ingelheim
-
Hampshire OperationalReviewing development application concerns following concerns over flawed traffic surveys in Hampshire.Moves Boehringer Ingelheim
Connections
The 15 strongest of 126, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Athens Structural
Boehringer Ingelheim maintains headquarters and manufacturing operations in Athens.
-
Pfizer Operational
Both Pfizer and Boehringer Ingelheim are actively competing in the development of improved GLP-1 drugs.
-
England Transactional
Boehringer Ingelheim supplies vaccines to England.
-
Johnson & Johnson Operational
Johnson & Johnson and Boehringer Ingelheim actively compete in the drug delivery and prostate cancer therapy markets.
-
American Lung Association Structural
Boehringer Ingelheim provides financial support to the American Lung Association.
-
Veterinary Medicines Directorate Operational
Boehringer Ingelheim actively coordinates with the Veterinary Medicines Directorate to secure vaccine approval.
-
Hampshire Operational
The relationship is characterized by an ongoing partnership between the company and the regional National Health Service (NHS) infrastructure.
-
Ridgefield Transactional
Boehringer Ingelheim is utilizing Ridgefield's services or location as part of approved storage structure plans.
Show all 15 connections
-
Korea Operational
Boehringer Ingelheim is actively seeking market opportunities and assets within the country of Korea.
-
AbbVie Operational
Both companies are discussed in the context of competitive M&A strategies within the pharmaceutical market.
-
Philippines Shared context
Boehringer Ingelheim operates within the Philippines, providing preventive care information to pet owners.
-
GSK Operational
The entities are observed to be competitors in the pharmaceutical market, facing shared product liability risks.
-
Gainesville Shared context
Boehringer Ingelheim maintains manufacturing operations within the geographic context of Gainesville.
-
Eli Lilly and Company Operational
Both pharmaceutical companies are currently reducing their presence in European markets.
-
Georgia Shared context
Boehringer Ingelheim maintains ongoing operations and investments within the state of Georgia.
History
Events by the month they beganSeptember 2026
5 events- Sheila Denton was appointed as General Counsel & Corporate Secretary at Boehringer Ingelheim.
- Boehringer Ingelheim and Palatin Technologies reported $13.2 million in revenue from their Fiscal 2026 collaboration.
- Boehringer Ingelheim reminds pet owners about preventive care in the Philippines.
- Commission approved Boehringer storage structure plans and safety improvements for a railroad crossing.
- AbbVie and Boehringer Ingelheim are engaging with financial advisory firms regarding potential deals and discussing M&A strategies in the competitive pharmaceutical market.
August 2026
3 events- Boehringer Ingelheim opened a new U.S. Animal Health headquarters in Gainesville and continues to invest in Georgia operations.
- WEG S.A., a Brazilian electric motor manufacturer, is linked to wealth derived from an inherited stake.
- Boehringer supplies vaccines to England and collaborates with the VMD, leading to disease spread into Scotland.
July 2026
3 eventsShow 1 earlier month
June 2026
13 events- Major pharmaceutical companies, including Eli Lilly, AstraZeneca, and Boehringer Ingelheim, are adjusting investments and operations in Europe.
- Boehringer Ingelheim and Immunai announced a collaboration focused on T-cell targets for drug discovery.
- Boehringer Ingelheim is seeking first-in-class assets in Korea.
- Boehringer Ingelheim announced a partnership with Americares that aims to improve global access to medicine.
- Proposed German drug pricing legislation is causing investment cuts and expansion cancellations for pharmaceutical companies.
- German drug pricing policy creates investment risk for pharmaceutical companies, including AstraZeneca and Boehringer Ingelheim.
- German drug pricing reform is causing Eli Lilly and Boehringer Ingelheim to withdraw from European markets.
- Dr. Kirk Shepard joined BP Logix's Life Sciences Strategic Advisory Board, leveraging his extensive background in the pharmaceutical industry.
- Elanco, Zoetis, and Boehringer Ingelheim are noted for their leadership in the veterinary dermatology market.
- Jyothis George held leadership roles at Amgen, Novo Nordisk, and Boehringer Ingelheim, driving strategic decisions on target indications and clinical trials.
- Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement, receiving FDA feedback on a Pre-IND Briefing Document.
- The FDA approved the Oncomine Dx Target Test, which identifies candidates for Boehringer Ingelheim's HERNEXEOS.
- Elanco is joining the S&P MidCap 400 index, Boehringer Ingelheim launched a new swine vaccine, and Sarepta Therapeutics is being replaced in the index.